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Other Uses of Morphine
Shrenik Ostwal
Abstract
Worldwide many different strong opioids and their formulations are available 
to control pain. Of which, morphine is considered as global opioid of choice and 
is widely used to control moderate to severe pain. The World Health Organization 
(WHO) has recommended morphine as one of the essential drug. Apart from anal-
gesic use, research has proven its effectiveness for relief and treatment of various 
debilitating and distressing conditions like breathlessness, mucositis (oral and vagi-
nal) and cough. However, its role in diarrhea and opioid substitution therapy (OST) 
is still nonconfirmatory. This chapter illustrates all available literature supporting 
effectiveness of morphine in above conditions and its impact on quality of life.
Keywords: morphine, dyspnoea, mucositis, chronic cough,  
opioid substitution therapy (OST), diarrhea
1. Introduction
Preparations of the opium poppy Papaver somniferum have been used for many 
hundreds of years to relieve pain. Morphine remains as the gold standard for manage-
ment of moderate to severe cancer pain. It has a five ringed structure with a character-
istic T-shaped three dimensional form essential for activation of the opioid receptor.
Due to its strong affinity to mu receptors and action similar to endorphins, i.e., 
natural pain killers, morphine has been widely used globally. Apart from its anal-
gesic action, it can be used widely for symptomatic relief of other distressing and 
debilitating conditions. This chapter depicts all available literature for various other 
uses of morphine.
2. Dyspnoea
2.1 Introduction
Dyspnoea, also termed as breathlessness, is a common and prevalent source 
of discomfort in patients with advanced cancer and non-cancer life limiting ill-
nesses. Most people describe it as an uncomfortable sensation or increased work of 
breathing in terms of air hunger, increased effort, chest tightness, rapid breathing, 
incomplete exhalation or feeling of suffocation.
The American Thoracic Society defined dyspnoea as “a subjective experience 
of breathing discomfort that consists of qualitatively distinct sensations that 
vary in intensity” [1]. This definition highlights key areas where dyspnoea can be 
measured, suggesting that dyspnoea is not merely a single sensation but a shared 
experience with physical and affective components. This is similar to concept of 
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total pain or total suffering which constitutes other domains like psychological, 
social, spiritual and environmental.
The prevalence of dyspnoea varies according to disease primary site and stage 
of illness. Studies by Muers and Round [2]; Smith et al. [3] reported prevalence of 
dyspnoea in 75–87% patients with primary lung cancer. While, a systematic review 
by Solano et al. [4] reported dyspnoea prevalence of: 90–95% in patients with 
chronic obstructive pulmonary disease (COPD), 60–88% in patients with heart 
disease, 11–62% in patients with AIDS and 11–62% in patients with renal disease. 
COPD and chronic heart failure (CHF) constitutes major non-cancer causes of 
dyspnoea in patients [5, 6].
Dyspnoea due to its prevalence and associated suffering poses a significant 
burden to patients and caregivers, hence severely affecting quality of life.
2.2 Pathophysiology of dyspnoea
Normally during unconscious activity, respiration is managed by clusters of neu-
rons in the medulla. They receive afferent input from several types of mechanore-
ceptors in respiratory muscles, airways, and lung parenchyma and chemoreceptors 
in aortic and carotid bodies and the medulla. Motor commands from the medulla 
or motor cortex by means of the medulla descend to respiratory muscles through 
efferent motor neurons [7, 8].
Differential diagnosis for dyspnoea in advanced cancer can be: (Table 1).
2.3 Opioids in breathlessness
The primary site of action of opioids in breathlessness is through medulla 
oblongata, although various mechanisms may be involved on effect on perception 
of breathlessness. Box 1 suggests various mechanisms by which morphine acts on 
breathlessness [1].
A study by Mahler et al. [9] in 2009 demonstrated threefold increase in beta 
endorphin levels in 17 COPD patients when compared from rest to end exercise. 
Patients were randomized to receive either normal saline or 10 mg of intravenous 
naloxone. Authors found significantly higher peak ratings and regression slope of 
breathlessness with naloxone as compared to normal saline. This study high-lighten 
role of endogenous opioids in dyspnoea modification in COPD patients.
Research has demonstrated role of oral morphine in breathlessness. However 
dosing schedule varies according to underlying condition. Box 2 depicts morphine 
dosing recommendations for breathlessness [10]:
• Analgesia—reduction of pain induced respiratory drive.
• Anxiolytic effects.
• Reduce minute ventilation.
• Cortical sedation (suppression of respiratory awareness).
• Alteration of neurotransmission within medullary respiratory center.
• Reduce central sensitivity and response to hypercarbia or hypoxia.
• Decreased metabolic rate and ventilatory requirements—decrease in O2 consumption.
• Vasodilatation and improved cardiac functions.
Box 1. Mechanism by which morphine reduces perception of breathlessness. Source: Adapted from American 
Thoracic Society guidelines on dyspnoea 2012.
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2.3.1 Morphine for breathlessness in cancer patients
There is good evidence for role of opioids in breathlessness [1, 5, 11–20]. Most 
of studies illustrated beneficial effect of morphine in breathlessness in cancer 
patients. Out of eight studies which evaluated effect of morphine in cancer related 
dyspnoea, seven were randomized controlled, double blind trials [21]. Another study 
by Clemens et al. [22], a non-randomized prospective study in advanced terminal 
cancer patients with dyspnoea, reported beneficial effect of morphine in reducing 
intensity of dyspnoea when compared with oxygen. While, Charles et al. [23] also 
reported similar and rapid improvement in breathlessness with use of nebulised 
hydromorphone. Studies by Bruera et al. [15] and Mazocato et al. [24] compared 
role of subcutaneous morphine with placebo in patients with primary lung cancer or 
lung metastases, showing a significant decrease in breathlessness intensity on visual 
analogue scale (VAS) after 45 min of intervention when treated with morphine. This 
was supported by a meta-analysis by Ben-Aharon et al. [10] in patients with cancer 
related dyspnoea. Authors found positive effect of opioids in reducing breathlessness.
Another two studies by Davis et al. (1996) and Grimbert et al. [25] reported 
no significant improvement in VAS scores even after 60 min of intervention with 
nebulized morphine when compared with placebo, i.e., nebulised saline. In one 
study Bruera et al. [15] compared effect of subcutaneous morphine with nebulised 
Malignant causes Non-malignant causes
Lung cancer/metastases to lung COPD/interstitial lung disease
Pleural effusion/pericardial effusion/ascites Bronchiectasis
Superior vena caval obstruction Congestive heart failure
Pulmonary embolism Arrhythmias
Pulmonary edema Motor neuron diseases
Major airway obstruction Muscular dystrophy
Lymphangitis carcinomatosis Anaemia
Chest wall infiltration Acidosis
Radiation induced pulmonary fibrosis Anxiety/panic attacks
Table 1. 
Causes of dyspnoea.
• Opioids should be started when disabling dyspnoea persists despite maximal Management of underlying 
condition.
• Check for renal, hepatic, pulmonary function, current and past opioid use.
• Prescribe laxatives and other supportive medications.
• Adopt policy of “Start Low and Go Slow” while titrating morphine dosage.
• Titrate morphine dose (up to 25–50% of dose for continued mild to moderate dyspnoea; and by up to 
50–100% of dose for continued moderate to severe dyspnoea) every weekly over 4 weeks until lowest 
effective dose is found.
• Start with 2.5–5 mg/4 h. PO or 1–2.5 mg/4 h. SC of morphine in opioid naive patients.
• For patients already prescribed morphine for pain, increase regular dose by 25–30%.
• Consider long acting twice daily morphine dosing in patients with stable regular dose.
• Consider 1/6th of regular dose prn for episodic breathlessness.
Box 2. Morphine dosing recommendations for breathlessness. Source: Adapted and developed from best practice 
for managing breathlessness in palliative care.
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morphine in lung primary patients, reporting no significant difference in dyspnoea 
intensity. However, this study reported patient’s preference with nebulised mor-
phine. Lastly, Allard et al. [26] found no significant differences in VAS score with 25 
or 50% increments in morphine dosages.
2.3.2 Morphine for breathlessness in COPD patients
A systemic review and meta-analysis by Jennings et al., comparing opioids with 
placebo for the treatment of dyspnoea [21] showed out of 18 randomized controlled 
trials (RCT) involved, nine trials reported patients receiving either oral opioids 
(n = 8) or subcutaneous morphine (n = 1). Such patients experienced significant 
beneficial effect with parenteral opioids on reducing dyspnoea when compared 
with placebo (meanΔ: –0.40; CI: −0.32 to −0.17). However, exercise was used as 
provoking stimulus to dyspnoea in eight of these nine studies, whereas only one 
study could examine patients with dyspnoea at rest.
Another randomized, double blind, placebo-controlled crossover trial by 
Abernethy et al. [27] compared 4 days of 20 mg oral sustained-release morphine 
with 4 days of oral placebo. Thirty-eight (87.5%) participants who were opioid 
naive and had dyspnoea at rest in spite of optimal therapy for their underlying 
condition (mainly patients with COPD) completed the trial. Patients on morphine 
experienced significant improvements (i.e., less dyspnoea and improved sleep) on 
VAS scale. Hence, authors concluded that “sustained release, oral morphine at low 
dosage provides significant symptomatic improvement in refractory dyspnoea in 
the community setting.”
2.3.3 Morphine for breathlessness in heart failure patients
Only few published studies have demonstrated positive outcomes with use of 
morphine in CHF related dyspnoea. In a pilot study by Johnson et al. [28] aimed to 
measure effect of oral morphine on breathlessness in patients with CHF, authors 
found a significant decrease in median breathlessness in those who received 5 mg 
of oral morphine four times a day (p = 0.022), whereas no change was observed in 
patients treated with placebo.
Oxberry et al. [29] conducted a crossover RCT on 35 patients diagnosed with 
CHF (New York Heart Association Grade III–IV) comparing 4 days of morphine 
(5 mg four times daily), oxycodone (2.5 mg four times daily) and placebo followed 
by a washout period of 3 days. Patients were followed up for 3 months. Authors 
found a significant improvement in composite breathlessness in opioid group as 
compared to placebo (p = 0.017). However they did not find any statistically signifi-
cant difference in breathlessness improvement in either intervention group. Hence, 
authors concluded need for long term trials to establish effectiveness of opioids.
Before stating opioids for dyspnoea in CHF patients, all possible etio-pathological 
causes should be taken into consideration. Non-pharmacological treatment options—
salt and fluid restriction, diet modification, appropriate exercise training and weight 
reduction strategies, etc., should be used first. Pharmacological therapy with angio-
tensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), 
beta blockers, diuretics, digoxin and implant devices should be optimally considered. 
Other possible causes like anaemia and pleural effusion should be taken care of.
2.3.4 Morphine for breathlessness in other conditions
A recent double blind study by Shohrati et al. [30] on 40 patients presented 
with dyspnoea due to mustard gas induced bronchiolitis obliterans reported 
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effectiveness of nebulised morphine (1 mg diluted in 4 cc normal saline). 
Patients experienced improvements in dyspnoea VAS score, cough, night time 
awakenings both due to dyspnoea and cough, heart rate, respiratory rate and 
overall quality of life.
A phase I clinical trial on six patients with interstitial lung disease (ILD) by 
Matsuda et al. [31] comparing two different doses of subcutaneous morphine injec-
tion demonstrated a tolerable dose of 2 mg to alleviate dyspnoea. However due to 
small sample size, results could not be reciprocated to general population and need 
for larger trials were recommended. On the other hand, Harris-Eze et al. [32] does 
not found any significant difference in exercise capacity and dyspnoea score in ILD 
patients treated with either 2.5 or 5 mg of nebulised morphine. This was supported 
by Cochrane review by Polosa et al. [33].
A single arm study of six patients with terminal amyotrophic lateral sclerosis 
(ALS) by Clemens et al. [22] showed effectiveness of morphine in reducing dys-
pnoea. Authors found a significant difference in respiratory rate and dyspnoea 
intensity at 120 min after morphine administration.
3. Role of morphine in mucositis
Mucositis refers to erythematous, erosive and ulcerative lesion of mucosa 
observed in patients with cancer treated with chemotherapy and/or radiotherapy 
to fields involving areas of body. Accordingly it may involve oral cavity, gastroin-
testinal tract, vaginal mucosa or other areas. Hence, manifesting as burning pain in 
mouth, diarrhea, vaginitis, etc. Elting et al. [34] observed chemotherapy-induced 
mucositis in 303 out of 599 patients (51%). Oral mucositis was developed in 22% 
cycles while gastrointestinal (GI) mucositis in 7% cycles.
3.1 Pathophysiology of mucositis
The five-stage model depicts various steps involved in pathogenesis of mucositis. 
Stages involved are [35]:
1. Stage of initiation of tissue injury
2. Stage of signaling through up regulation of inflammation via generation of 
messenger signals
3. Stage of amplification
4. Stage of ulceration and inflammation
5. Stage of healing
3.2 Morphine and oral mucositis
Oral mucositis poses a significant source of pain and distress to patients receiv-
ing chemotherapy or radiotherapy to head and neck area. It often manifests as 
burning pain, ulcers, erythematous lesions in mouth complicated by secondary 
infections—bacterial/fungal/viral. It significantly affects nutritional intake, oral 
hygiene and overall quality of life. Infections associated with oral mucositis may 
pose life-threatening conditions. Adequate oral hygiene and treatment of underly-
ing cause helps to relieve symptoms and distress in patients [36, 37].
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Various combination of local measures helps to take care of mucositis-related 
complications. Research has shown effectiveness of morphine gargles either alone 
(morphine rinse) or in combination with antacid, lignocaine viscous and dex-
tromethorphan (magic mouth wash), in relieving pain and symptoms related to 
mucositis. A mini review by Dutta et al. [38] compared six studies using morphine 
as oral rinse. All studies showed satisfactory result in terms of pain control, mouth 
opening and patient preferences. This is supported by other studies which proved 
efficacy of morphine gargles [36, 37, 39–44].
3.3 Morphine and vaginal mucositis
Vaginitis, also known as vaginal mucositis is an acute inflammation with ery-
thema and erosion of vaginal mucosa leading to severe vaginal pain, per vaginal 
discharge and/or associated complications. It is commonly seen in patients with 
local infection or as a part of systemic infection, as a complication to radiotherapy 
to local areas or chemotherapy, recto-vaginal fistula, trauma, etc. Morphine, similar 
to its role in oral mucositis can be considered for vaginal mucositis. A case reported 
by Ostwal et al. [45] showed efficacy of morphine when combined with vaginal 
douche (magic vaginal douche—metronidazole, normal saline, povidone iodine 
solution, lignocaine viscous with 20 mg crushed tab morphine) in relief from 
symptoms of vaginal mucositis. However RCTs are not available and are required to 
prove its clinical efficacy.
4. Role of morphine in chronic cough
4.1 Introduction
Cough is found to be prevalent in around 65% patients with lung cancer [46] 
and 70% patients with COPD [47, 48]. Persistent or chronic cough can have vari-
ous physical complications like musculoskeletal pain over chest wall, rib fracture, 
bowel and bladder incontinence, disturbed sleep and feeling of exhaustion. Patients 
usually experience psychological impacts, social isolation and decreased quality of 
life [48].
Cough reflex is regulated by vagal afferent pathways, nucleus tractus solitarius 
(NTS) in brainstem, and cough center in cerebral cortex. Common underlying 
patho-physiological causes for cough includes: (i) infection; (ii) lung cancer or 
secondary metastases to lung/pleura/mediastinum/pericardium/blood vessels; 
(iii) COPD, ILD, bronchiectasis; (iv) aspiration; (v) asthma/bronchospasm; (vi) 
esophageal reflux; (vii) tracheo-esophageal fistula; (viii) radiotherapy or chemo-
therapy induced pulmonary fibrosis; (ix) ACE inhibitors; (x) pulmonary edema/
left ventricular failure, etc. Timely and proper assessment of cough with removal of 
underlying cause can decrease distress and improve patients’ quality of life.
4.2 Morphine and cough
Research work by Kamei [49] showed involvement of mu opioid receptors in 
production of cough. Very limited studies are available for use of morphine on 
chronic cough [47, 50–56]. Strongest evidence for effectiveness of morphine in 
chronic cough was shown in a double blind placebo controlled trial by Morice 
et al. [57]. Twenty seven patients with chronic persistent cough were assigned to 
4 weeks of slow release morphine sulfate (5 mg twice daily escalated to 10 mg twice 
daily) matched correspondingly with placebo. A significant improvement of 3.2 
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points over baseline, and 40% rapid reduction in cough frequency and severity was 
observed in slow release morphine group (p < 0.01). Dose comparison over 3 month 
period between 5 and 10 mg did not showed any significant difference, helping to 
conclude study with daily dose recommendation of slow release morphine sulfate 
from 5 to 10 mg twice daily.
5. Role of morphine in diarrhea
Diarrhea has been defined as “passage of ≥3 loose or watery bowel movements 
per day or passage of ≥200 g of stool per day based on typical diet.” Diarrhea can be 
acute (<14 days), persistent (>14 days but <30 days) or chronic (>30 days) based 
on its duration. Diarrhea poses a common and significant problem in patients with 
cancer. It may be due to either local infection, as a part of systemic inflammation/
infection, as a complication to radiotherapy or chemotherapy [58], etc.
Mechanism for diarrhea can be attributed to increased intestinal motility  
[59, 60]. Hence drugs which act to decrease intestinal motility are found to be help-
ful in treatment. Morphine and other opiates (loperamide, diphenoxylate, codeine) 
act on intestinal mu-receptors and slow intestinal transit time, thus increasing net 
absorption [61, 62]. Though constipation is commonly seen as a side effect with 
morphine use, research considering use of this side effect to treat diarrhea has not 
been done. Clinical Practice guidelines by European Society for Medical Oncology 
(ESMO) has documented role of tincture of opium like morphine (10 mg/mL 
morphine) in treatment with diarrhea as an alternative to loperamide. The recom-
mended dose of tincture morphine is 10–15 drops in water every 3–4 h [58, 63], [64].  
Till date robust studies supporting this has not been available.
6. Morphine and opioid substitution therapy (OST)
Morphine has been known for its potential effect in analgesia since last few 
decades. However, it is also known for its potential to cause addiction and depen-
dence. Opium, derived naturally from poppy plant is widely used for addiction. 
Opioid substitution therapy (OST) is an evidence-based intervention for opiate 
dependent persons that replaces illicit drug use with medically prescribed, orally 
administered opiates such as buprenorphine and methadone. OST reduces HIV risk 
behaviors and harms associated with injecting (such as abscesses, septicemia and 
endocarditis), overdose and participation in criminal activity, thereby improving 
the quality of life and health of injecting drug users (IDUs).
Work by Hämmig et al. [65] showed that slow release oral morphine (SROM) 
preparations can be used as OST for heroin addicted patients. Authors found 
higher treatment satisfaction, fewer cravings for drug and less mental stress with 
SROM. Cochrane review by Ferri et al. [65] found only three randomized controlled 
trials which included SROM for OST. Out of three, only two studies suggested 
possible role of SROM formulations; while remaining study was associated with 
adverse events like depressive symptoms [65–70]. Hence authors concluded for 
necessity of more robust and clinically controlled trials.
7. Conclusion
Morphine, a potent and strong opioid, has shown its efficacy in relieving variety 
of distressing symptoms. Research has documented role of low dose morphine for 
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